On Nov. 11, 2021, Innovation Pharma reported topline results from the Companyﾒs Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19. Brilacidin is being developed for treatment of COVID-19 under FDA Fast Track designation.

Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the studyﾒs primary endpoint based on clinical status.